![logo](/logos/IGMS.webp)
IGM Biosciences, Inc.
NASDAQ:IGMS
9.31 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | IGM Biosciences, Inc. |
Symbool | IGMS |
Munteenheid | USD |
Prijs | 9.31 |
Beurswaarde | 552,256,808 |
Dividendpercentage | 0% |
52-weken bereik | 3.81 - 17.7 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Fred M. Schwarzer J.D. |
Website | https://igmbio.com |
An error occurred while fetching data.
Over IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)